Analyst Vamil Divan works at GUGGENHEIM and is focused on the Healthcare sector with 494 price targets and ratings documented since 2013 spanning on 21 stocks. Previously, Vamil Divan worked at MIZUHO, CREDIT SUISSE. Analyst's average stock valuation to be materialised ratio is 65.68% with an average time for price targets to be met of 209.75 days.
Most recent stock forecast was given on ABBV, AbbVie Inc at 01-Mar-2023.
Vamil Divan best performing recommendations are on KRTX (KARUNA THERAPEUTICS, INC).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS, INC) at 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%) receiving and performance score of 69.38.
Average potential price target upside
Currently, out of the existing stock ratings of Vamil Divan - 10903 which are a Hold (35.22%), 19242 which are a Buy (62.15%), 816 which are a Sell (2.64%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
172
$13.98 (8.85%)
166
24 days ago
23/24 (95.83%)
$22.93 (27.45%)
344
Sell
153
$-5.02 (-3.18%)
135
1 months 15 days ago
20/20 (100%)
$19.5 (30.42%)
515
Buy
163
$4.98 (3.15%)
157
1 months 15 days ago
34/35 (97.14%)
$24.2 (28.52%)
414
Sell
153
$-5.02 (-3.18%)
92
1 months 15 days ago
6/6 (100%)
$25.57 (55.74%)
574
Hold
154
$-4.02 (-2.54%)
157
1 months 15 days ago
4/4 (100%)
$15.03 (18.69%)
198